Subscribe
Be the first with the news that moves the market- SQI Diagnostics (SQD) has appointed Robert L Chioini to the role of Chief Executive Officer
- Robert has over 30 years of experience in the medical industry, much of which he spent at Rockwell Medical
- Under his employment agreement, Robert will also serve as CEO of the company’s subsidiaries, SQI US and SQI Diagnostics Systems
- He will take over as the company moves to advance its product portfolio, which includes COVID-19 severity assessment tests
- SQI Diagnostics (SQD) is down 2.50 per cent and is currently trading at C$0.20 per share
SQI Diagnostics (SQD) has appointed Robert L Chioini to the role of Chief Executive Officer.
Robert will take over for Eric Brouwer, who has been serving as the company’s Interim CEO. Eric will continue in his role as SQI’s Chief Scientific Officer, as well as a company director.
In addition to the top job, Robert has also been appointed as a director of the company, as of August 17, 2020. Under his employment agreement, he will additionally serve as the CEO of SQI’s wholly owned subsidiaries, SQI US and SQI Diagnostics Systems.
Robert has over 30 years of operational and business development experience in the medical industry. He spent much of that time as the Chairman and CEO of Rockwell Medical, a Nasdaq-listed medical device and biopharmaceutical company which he founded.
Robert is taking over as SQI moves to advance its product portfolio, which includes COVID-19 severity assessment tests. Demand for such tests remains high, as the pandemic continues to cut a swathe through nations worldwide.
The Chairman of the Board at SQI, Clive J Beddoe, welcomed Robert to his new position within the company.
“Rob is a successful entrepreneur and experience CEO, who has an exceptional track record of identifying and developing new product and revenue stream opportunities.
“His experience in marketing and commercialising novel products to capture market share and strengthen company brand will be invaluable as we advance our product portfolio, including our COVID-19 severity assessment tests.
“He is a seasoned leader with significant understanding of public markets, corporate growth, and delivering value to shareholders. I look forward to Rob’s leadership, and we are fortunate to have him as our CEO,” he said.
Robert stated that he is incredibly excited about assuming the role of CEO at SQI, and about the future of the company.
“I look forward to working with the team to unlock the potential across our suite of clinical and point-of-care diagnostic products.
“Now more than ever, we see the importance of accurate, widely available, and rapid diagnostic tests,” he said.
SQI Diagnostics (SQD) is down 2.50 per cent and is trading for C$0.20 per share at 11:43am EDT.
